Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sinovac Announcement On H1N1 Vaccine Phase I Results Criticized

This article was originally published in PharmAsia News

Executive Summary

China's Sinovac Biotech has drawn criticism from some in the industry for promoting its H1N1 flu vaccine before it has completed the clinical trial process. They note that Hualan Biological Engineering also has a vaccine in trials, but has not made public announcements about its progress so far. One critic noted that Sinovac's announcement of Phase I results means only that it was safe for the few people in the initial trial. China has 10 vaccine producers with permission to develop a vaccine against the flu. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts